SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-1.63%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$527M
AUM Growth
+$527M
(-12%)
Cap. Flow
-$29.5M
Cap. Flow
% of AUM
-5.61%
Top 10 Holdings %
Top 10 Hldgs %
65.74%
Holding
74
New
14
Increased
17
Reduced
12
Closed
23
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$32.5M |
| 2 |
Eli Lilly
LLY
|
$20.1M |
| 3 |
Nice
NICE
|
$10.7M |
| 4 |
FIVE9
FIVN
|
$10.1M |
| 5 |
Amicus Therapeutics
FOLD
|
$8.09M |
Top Sells
| 1 |
Pfizer
PFE
|
$26.7M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$16.3M |
| 3 |
Kymera Therapeutics
KYMR
|
$15.6M |
| 4 |
ZIM Integrated Shipping Services
ZIM
|
$10.8M |
| 5 |
Generac Holdings
GNRC
|
$8.39M |
Sector Composition
| 1 | Healthcare | 83.89% |
| 2 | Technology | 5.42% |
| 3 | Communication Services | 1.53% |
| 4 | Financials | 0.47% |
| 5 | Consumer Discretionary | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AstraZeneca
AZN
$248B
| $52.8M | 5.64% | 798,610 -38,207 | -5% | -$2.52M |
|
2
Johnson & Johnson
JNJ
$427B
| $49.1M | 5.25% | 276,451 -18,572 | -6% | -$3.3M |
|
|
3
Eli Lilly
LLY
$657B
| $42.9M | 4.59% | 132,250 +61,955 | +88% | +$20.1M |
|
4
Sanofi
SNY
$121B
| $42.3M | 4.53% | 846,215 -126,200 | -13% | -$6.31M |
|
5
AbbVie
ABBV
$372B
| $33.4M | 3.58% | 218,385 +27,391 | +14% | +$4.2M |
|
|
6
SPDR S&P Biotech ETF
XBI
$5.07B
| $32.5M | 3.48% | +437,748 | New | +$32.5M |
|
7
Novo Nordisk
NVO
$251B
| $29.1M | 3.12% | 261,440 +24,040 | +10% | +$2.68M |
|
8
Merck
MRK
$210B
| $26M | 2.78% | 285,000 +6,800 | +2% | +$620K |
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $21.9M | 2.34% | 1,139,329 -138,084 | -11% | -$2.66M |
|
10
Altimmune
ALT
$338M
| $16.3M | 1.74% | 1,392,884 +85,931 | +7% | +$1.01M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $13.2M | 1.41% | 536,664 +76,639 | +17% | +$1.89M |
|
|
12
FIVE9
FIVN
$2.08B
| $12.8M | 1.37% | 140,968 +111,269 | +375% | +$10.1M |
|
|
KDNY
13
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.3M | 1.2% | 643,731 +150,054 | +30% | +$2.62M |
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.9M | 1.17% | 586,820 +64,873 | +12% | +$1.21M |
|
|
15
Nice
NICE
$8.73B
| $10.7M | 1.14% | +55,482 | New | +$10.7M |
|
16
Merus
MRUS
$4.98B
| $9.26M | 0.99% | 409,161 +20 | +0% | +$453 |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.26M | 0.99% | 962,470 +188,340 | +24% | +$1.81M |
|
18
Kura Oncology
KURA
$686M
| $9.07M | 0.97% | 494,595 -123,649 | -20% | -$2.27M |
|
19
Relmada Therapeutics
RLMD
$37.2M
| $8.87M | 0.95% | 466,830 +175,578 | +60% | +$3.33M |
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| $8.63M | 0.92% | 1,147,878 +315,000 | +38% | +$2.37M |
|
|
21
Amicus Therapeutics
FOLD
$2.34B
| $8.09M | 0.87% | +753,037 | New | +$8.09M |
|
22
Meta Platforms (Facebook)
META
$1.86T
| $8.06M | 0.86% | +50,000 | New | +$8.06M |
|
23
Immatics
IMTX
$619M
| $6.37M | 0.68% | 730,712 +108,787 | +17% | +$948K |
|
|
INZY
24
DELISTED
Inozyme Pharma
INZY
| $5.56M | 0.59% | +1,165,600 | New | +$5.56M |
|
25
C4 Therapeutics
CCCC
$185M
| $5.32M | 0.57% | 705,736 +343,208 | +95% | +$2.59M |
|